CTOs on the Move


 
Afaxys mission is to deliver products and services to public health providers affordably, reliably and with an unwavering focus on customer service.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.afaxys.com
  • 455 1/2, King St
    Charleston, SC USA 29403
  • Phone: 855.888.2467

Executives

Name Title Contact Details

Similar Companies

Javan Engineering Inc

Javan Engineering Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KORU Medical

The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.

Exela Pharma Sciences

Exela Pharma Sciences is a Lenoir, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Laboratory Diagnostics

Find local doctors and healthcare providers near you. See their ratings, reviews, contact info, address, profile, and more.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.